BiondVax Pharma surges as former GSK exec joins board
28/12/2021 11:24
** U.S. shares of Israel-based biopharmaceutical BiondVax
Pharmaceuticals BVXV.O up 70.4% at $3.97 premarket, set to
break 2 straight days of losses
** Jay Green, former chief finance officer (CFO) of
GlaxoSmithKline plc's GSK.N global vaccines business, joins
BiondVax's board of directors urn:newsml:reuters.com:*:nASA02WJ1
** BVXV on Dec 22 gained 97.3%, its best day ever, after co
agreed to development and commercialization of nanosized
COVID-19 antibody therapy with Germany-based research firms
urn:newsml:reuters.com:*:nL4N2T72LM
** "Jay's experience serving as GSK Vaccine's SVP
Finance/CFO and his current involvement in the global COVID–19
response as an advisor to Gavi for COVAX is highly relevant" -
BVXV's chairman
** More than 1.75 mln shares of BVXV traded as of 1103 GMT -
top premarket mover on Nasdaq
** Up to last close, stock down ~17% so far this year
(Reporting by Bansari Mayur Kamdar in Bengaluru)
((BansariMayur.Kamdar@thomsonreuters.com;))